NCT07777822Phase 3Recruiting

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Study sponsor: Revolution Medicines, Inc. · RVMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-10Estimated
Enrollment · participants430Estimated
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.